Should I Buy ATXS? ATXS 2026 Analysis

Should You Buy Astria Therapeutics Inc (ATXS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1 Day change

0.64%

52 Week Range

13.290

Analysis Updated At

2026/01/23

Astria Therapeutics Inc (ATXS) is not a strong buy for a beginner, long-term investor at this time. The technical indicators are neutral, options data suggests a lack of strong trading sentiment, and there are no significant positive catalysts or recent news to drive the stock higher. Additionally, the downgrade by Cantor Fitzgerald and the company's negative financial performance, despite some YoY improvement, make it prudent to hold off on investing for now.

Technical Analysis

The MACD histogram is negative (-0.0615) and contracting, RSI is neutral at 44.865, and moving averages are converging, indicating no clear trend. Support and resistance levels suggest limited immediate upside potential with a pivot at 12.718, resistance at 13.111, and support at 12.324.

Options Data

Neutral

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The open interest put-call ratio of 1.02 indicates a slight bearish sentiment, while the absence of option volume suggests low trading activity and interest in the stock.

Technical Summary

Sell

Buy

Positive Catalysts

NULL. There are no recent news events, significant trading trends, or congress trading data to act as positive catalysts.

Neutral/Negative Catalysts

Cantor Fitzgerald downgraded the stock to Neutral from Overweight. Additionally, the financials show a net loss of -31.64M in Q3 2025, albeit with some YoY improvement.

Financial Performance

In Q3 2025, revenue remained flat at $706,000 YoY. Net income improved by 28.98% YoY but remains negative at -31.64M. EPS improved by 30.95% YoY to -0.55. Gross margin stayed at 100%. Overall, the company is still unprofitable.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Cantor Fitzgerald downgraded the stock to Neutral from Overweight on 2025-11-12, signaling reduced confidence in the stock's performance.

7 Analyst Rating

Wall Street analysts forecast ATXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATXS is 13 USD with a low forecast of 13 USD and a high forecast of 13 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

7 Hold

0 Sell

Hold

Current: 12.580

Low

Averages

High

Current: 12.580

Low

Averages

High

Cantor Fitzgerald

Overweight

Neutral

downgrade

AI Analysis

2025-11-12

Reason

Cantor Fitzgerald

Price Target

AI Analysis

2025-11-12

downgrade

Overweight

Neutral

Reason

Cantor Fitzgerald downgraded Astria Therapeutics to Neutral from Overweight.

H.C. Wainwright

Buy -> Neutral

downgrade

2025-10-16

Reason

H.C. Wainwright

Price Target

2025-10-16

downgrade

Buy -> Neutral

Reason

H.C. Wainwright downgraded Astria Therapeutics to Neutral from Buy without a price target after the company agreed to be acquired by BioCryst (BCRX) for a mix of cash and stock representing an implied value of $13 per share.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ATXS

Unlock Now

ATXS Should I Buy

ATXS Should I Buy

Should You Buy Astria Therapeutics Inc (ATXS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch